Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2019 /
Umbralisib as a monotherapy in patients with relapsed/refractory marginal zone lymphoma

29th Mar - 3rd Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.04.19
Views: 640

Prof Nathan Fowler - MD Anderson Cancer Center, Houston, USA

Prof Nathan Fowler speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about the use of umbralisib in the treatment of relapsed/refractory marginal zone lymphoma.

Prof Fowler reports the findings of this phase II clinical trial; in which an overall response rate of 52 percent was achieved and predicts 66 percent of patients will achieve progression-free survival after one year.

In the next few years, Prof Fowler hopes that the results from this trial will lead to the FDA-approval of umbralisib for use in these patients - potentially in the first-line setting and in combination with chemotherapy.

Read more about this research here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation